Ultrasound renal denervation for hypertension: impact of the RADIANCE-HTN-TRIO trial on future management of resistant hypertension
- 4 October 2021
- journal article
- editorial
- Published by Elsevier BV in Kidney International
- Vol. 101 (1), 6-9
- https://doi.org/10.1016/j.kint.2021.09.017
Abstract
No abstract availableFunding Information
- Vanderbilt University Medical Center
This publication has 9 references indexed in Scilit:
- Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN TRIO): a randomised, multicentre, single-blind, sham-controlled trialThe Lancet, 2021
- Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trialThe Lancet, 2018
- Effect of renal denervation on blood pressure in the presence of antihypertensive drugs: 6-month efficacy and safety results from the SPYRAL HTN-ON MED proof-of-concept randomised trialThe Lancet, 2018
- Catheter-based renal denervation in patients with uncontrolled hypertension in the absence of antihypertensive medications (SPYRAL HTN-OFF MED): a randomised, sham-controlled, proof-of-concept trialThe Lancet, 2017
- Renal denervation in comparison with intensified pharmacotherapy in true resistant hypertensionJournal of Hypertension, 2017
- Residual Cardiovascular Risk in Individuals on Blood Pressure–Lowering TreatmentJournal of the American Heart Association, 2015
- A Controlled Trial of Renal Denervation for Resistant HypertensionThe New England Journal of Medicine, 2014
- Substantial Reduction in Single Sympathetic Nerve Firing After Renal Denervation in Patients With Resistant HypertensionHypertension, 2013
- SPLANCHNICECTOMY FOR ESSENTIAL HYPERTENSIONJournal of the American Medical Association, 1953